Only about 40% of triple-negative breast cancers are PD-L1+; not all PD-L1+ patients with advanced triple-negative breast cancer respond, and immunotherapy is not yet approved for advanced PD-L1-negative triple-negative breast cancer, HER2 + breast cancer, or ER + breast cancer. Here, CD274 is linked to breast carcinoma.